Biomarker repurposing: Therapeutic drug monitoring of serum theophylline offers a potential diagnostic biomarker of Parkinson’s disease
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Biomarker repurposing: Therapeutic drug monitoring of serum theophylline offers a potential diagnostic biomarker of Parkinson’s disease
Authors
Keywords
Parkinson disease, Biomarkers, Caffeine, Drug metabolism, Immunoassays, Metabolites, Therapeutic drug monitoring, Diagnostic medicine
Journal
PLoS One
Volume 13, Issue 7, Pages e0201260
Publisher
Public Library of Science (PLoS)
Online
2018-07-26
DOI
10.1371/journal.pone.0201260
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Serum caffeine and metabolites are reliable biomarkers of early Parkinson disease
- (2018) Motoki Fujimaki et al. NEUROLOGY
- Metabolomic biomarkers as strong correlates of Parkinson disease progression
- (2017) Peter A. LeWitt et al. NEUROLOGY
- Caffeine consumption and the 4-year progression of de novo Parkinson's disease
- (2016) Marcello Moccia et al. PARKINSONISM & RELATED DISORDERS
- Identification of novel biomarkers for Parkinson's disease by metabolomic technologies
- (2015) Taku Hatano et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- MDS clinical diagnostic criteria for Parkinson's disease
- (2015) Ronald B. Postuma et al. MOVEMENT DISORDERS
- MDS research criteria for prodromal Parkinson's disease
- (2015) Daniela Berg et al. MOVEMENT DISORDERS
- Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study
- (2015) Niels Kruse et al. NEUROBIOLOGY OF AGING
- Facilitating the Validation of Novel Protein Biomarkers for Dementia: An Optimal Workflow for the Development of Sandwich Immunoassays
- (2015) Marta del Campo et al. Frontiers in Neurology
- The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative
- (2014) José Luis Molinuevo et al. Alzheimers & Dementia
- Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease
- (2014) Daniela Berg et al. MOVEMENT DISORDERS
- CSF biomarker variability in the Alzheimer's Association quality control program
- (2013) Niklas Mattsson et al. Alzheimers & Dementia
- Dose-response meta-analysis on coffee, tea and caffeine consumption with risk of Parkinson's disease
- (2013) Hui Qi et al. Geriatrics & Gerontology International
- Adenosine A2Areceptor antagonist istradefylline reduces daily OFF time in Parkinson's disease
- (2013) Yoshikuni Mizuno et al. MOVEMENT DISORDERS
- Meta-analysis of early nonmotor features and risk factors for Parkinson disease
- (2012) Alastair J. Noyce et al. ANNALS OF NEUROLOGY
- Caffeine for treatment of Parkinson disease: A randomized controlled trial
- (2012) R. B. Postuma et al. NEUROLOGY
- Detection of elevated levels of -synuclein oligomers in CSF from patients with Parkinson disease
- (2010) T. Tokuda et al. NEUROLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started